Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

GSK And Nabi Developing Smoking Vaccine

By Drug Discovery Trends Editor | November 18, 2009

NEW YORK (AP) – GlaxoSmithKline PLC and Nabi Biopharmaceuticals said Monday they will work together to develop vaccines to help smokers give up the habit, in a deal that could be worth more than $500 million.

Nabi is developing a vaccine called NicVAX, which is intended to train the immune system to make antibodies that will attach themselves to nicotine. With the antibodies stuck to them, the nicotine molecules will not be able to reach the brain. The companies say that will block the pleasurable effects of nicotine.

In the deal, Nabi will get $40 million upfront and complete testing of NicVAX. GlaxoSmithKline, which is based in London, will also start developing a second-generation version of the vaccine.

Nabi, of Rockville, Md., is running one late-stage clinical study of NicVAX and plans to start another one. If testing is successful, GlaxoSmithKline will be responsible for getting the vaccine approved by regulators, and will market the drug if it is approved.

Nabi could receive milestone payments for successful testing, regulatory approval and sales targets, as well as royalties of more than 10 percent on sales. The companies said those payments could reach more than $500 million. The deal is expected to close in the first quarter of 2010.

The companies said there are about 1.2 billion smokers in the world, and smoking causes 5.4 million deaths per year.

Date: November 16, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE